TTK Healthcare Intrinsic Value
TTK Healthcare (TTKHLTCARE) median intrinsic value is ₹523.60 from 9 valuation models (range ₹314–₹913), vs current price ₹1047.20 — -50.0% downside (Trading Above Calculated Value), margin of safety -100.0%. Read TTKHLTCARE dividend track record for the complete payout history and dividend yield track record.
TTKHLTCARE Valuation Methods Summary — DCF, Graham Number & P/E
TTK Healthcare intrinsic value across 9 models vs current price ₹1047.20 — upside/downside and value range per method. For current market price and key ratios, visit TTK Healthcare share price chart.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹557.76 | ₹446.21 - ₹669.31 | -46.7% | EPS: ₹46.48, Sector P/E: 12x |
| Book Value Method | asset | ₹796.43 | ₹716.79 - ₹876.07 | -23.9% | Book Value/Share: ₹796.43, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹530.86 | ₹477.77 - ₹583.95 | -49.3% | Revenue/Share: ₹663.57, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹420.00 | ₹378.00 - ₹462.00 | -59.9% | EBITDA: ₹98.00Cr, EV/EBITDA: 6x |
| PEG Ratio Method | growth | ₹450.05 | ₹405.05 - ₹495.06 | -57.0% | EPS Growth: 12.1%, Fair P/E: 9.7x |
| Growth Adjusted P/E | growth | ₹391.95 | ₹352.75 - ₹431.15 | -62.6% | Revenue Growth: 10.8%, Adj P/E: 8.4x |
| ROE Based Valuation | profitability | ₹523.60 | ₹471.24 - ₹575.96 | -50.0% | ROE: 5.9%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹912.64 | ₹821.38 - ₹1003.90 | -12.8% | EPS: ₹46.48, BVPS: ₹796.43 |
| Dividend Yield Method | dividend | ₹314.16 | ₹282.74 - ₹345.58 | -70.0% | DPS: ₹10.00, Target Yield: 3.5% |
TTKHLTCARE Intrinsic Value vs Market Price — All Valuation Models
TTK Healthcare fair value range ₹314–₹913 vs current market price ₹1047.20 across 9 valuation models. Analyse TTKHLTCARE institutional holdings to track promoter, FII and institutional holdings.
TTKHLTCARE Intrinsic Value Analysis — Undervalued or Overvalued?
TTK Healthcare median intrinsic value ₹523.60, current price ₹1047.20 — Trading Above Calculated Value by 50.0%, margin of safety -100.0%.
What is the intrinsic value of TTKHLTCARE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of TTK Healthcare (TTKHLTCARE) is ₹523.60 (median value). With the current market price of ₹1047.20, this represents a -50.0% variance from our estimated fair value.
The valuation range spans from ₹314.16 to ₹912.64, indicating ₹314.16 - ₹912.64.
Is TTKHLTCARE undervalued or overvalued?
Based on our multi-method analysis, TTK Healthcare (TTKHLTCARE) appears to be trading above calculated value by approximately 50.0%.
TTKHLTCARE Financial Health — Key Ratios vs Industry Benchmarks
TTK Healthcare financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 152.25 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.70x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
TTKHLTCARE Cash Flow Quality — Operating & Free Cash Flow
TTK Healthcare operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-21 Cr | ₹-21 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-4 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-5 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-25 Cr | ₹-25 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹45 Cr | ₹30 Cr | Positive Free Cash Flow | 8/10 |